Drug intelligence / Profile preview

AbGn-7

Development stage: Phase 1
Lead developer: AbGenomics International
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AbGn-7 is a chimeric monoclonal antibody that targets a Lewis-A-like carbohydrate antigen (referred to as the AbGn-7 antigen) expressed on certain gastrointestinal cancer cells, including colorectal cancer. It has demonstrated immunomodulating and antineoplastic activities in preclinical studies, triggering apoptosis in colon cancer cells via a caspase-independent pathway and eliciting complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody was developed for potential use in treating colorectal cancer and other gastrointestinal malignancies. Its development was led by AbGenomics International[2][4].

Targets

AG7 (Lewis-A-like carbohydrate antigen)

Beyond the preview

Go deeper on AbGn-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbGn-7.

Explore the full profile